Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars

Inclusion Criteria

• Fitzpatrick Skin Type I - IV
• Has postoperative linear scar(s) which is one to twelve months post-surgery.
• Having one scar that measures a minimum of 5 cm in length or two scars (bilateral) each measure a minimum of 2 cm in length.
• Be in good health.
• Must agree not to undergo any other procedure for the treatment of scar during the study.
• Willing to refrain from excess sun exposure and willing to wear sunscreen on the treated scar during the study (including the follow-up period).
• Able to read, understand and sign the Informed Consent Form.
• Willing and able to adhere to the treatment and follow-up schedule, and the post-treatment care instructions.
• Willingness to have digital photographs taken of the treated scar.
• Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.

Exclusion Criteria

• Participation in a study of another device or drug within 6 months prior to enrollment or during the study.
• Having received any prior treatment for the target surgical scar.
• Pregnant and/or breastfeeding.
• Significant concurrent illness, malignant tumors in the target area, acute or chronic skin infection/inflammation, currently using immunosuppressive medications or currently undergoing systemic chemotherapy.
• Current use of any medication known to increase sensitivity to light or taking prescription anticoagulation medication.
• History of abnormal or delayed wound healing, keloid formation or pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
• History of malignant skin disease, immune deficiency disorders, coagulation disorders, seizure disorders due to light, or diseases stimulated by heat, unless prophylactic measures taken prior to treatment.
• Systemic use of isotretinoin within 6 months or corticosteroids within 12 months of study participation.
• Anytime in life, had used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
• Current smoker or history of smoking within 12 months of study participation.